Los Angeles Capital Management LLC Acquires New Holdings in Altimmune, Inc. $ALT

Los Angeles Capital Management LLC bought a new position in Altimmune, Inc. (NASDAQ:ALT) in the 2nd quarter, HoldingsChannel reports. The fund bought 13,947 shares of the company’s stock, valued at approximately $54,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Bank of New York Mellon Corp increased its position in Altimmune by 1.2% in the 1st quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company’s stock valued at $945,000 after acquiring an additional 2,162 shares during the period. Brown Wealth Management LLC increased its holdings in shares of Altimmune by 100.0% during the first quarter. Brown Wealth Management LLC now owns 100,024 shares of the company’s stock valued at $500,000 after purchasing an additional 50,024 shares during the period. Federated Hermes Inc. bought a new stake in shares of Altimmune during the first quarter valued at about $939,000. Jefferies Financial Group Inc. bought a new stake in shares of Altimmune during the first quarter valued at about $125,000. Finally, Headland Capital LLC acquired a new stake in Altimmune in the first quarter worth about $50,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Price Performance

NASDAQ ALT opened at $4.65 on Wednesday. Altimmune, Inc. has a 1 year low of $2.90 and a 1 year high of $10.88. The business’s fifty day moving average is $3.95 and its two-hundred day moving average is $4.48. The stock has a market capitalization of $485.19 million, a P/E ratio of -3.94 and a beta of 0.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%. On average, research analysts forecast that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. UBS Group dropped their price target on shares of Altimmune from $26.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. Citigroup reissued a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research report on Monday, October 20th. Wall Street Zen upgraded Altimmune from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Altimmune in a report on Monday. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $16.83.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.